Biosynthetic Corneas Show Initial Promise

The results of a 2-year Phase I clinical study of implantable human type III collagen biosynthetic corneas shows promising results.  Quite the mouthful, but the biosynthetic corneas developed by FibroGen, Inc. could be a viable alternate to cornea transplants.  The patients in the study did not require immunosuppressive treatment and tissue regrowth within the implant matrix was noted.  Check out the links below for more info.

Sources:
Science Translational Medicine Journal
EurekAlert
Medpage Today